Clinical trials: Ischemic Stroke
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
- Trial name
- NCT01958957
- Testing
- Ginkgolides Meglumine Injection
- Where
- 86 sites in China
- Volunteers
- 6,300 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Cerebral Infarction
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral…
- Trial name
- CSPS (NCT00766545)
- Testing
- cilostazol
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Stroke
Desmoteplase in Acute Ischemic Stroke (DIAS)
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after…
- Trial name
- NCT00638781
- Testing
- Desmoteplase
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- PAION Deutschland GmbH
Acute Ischemic Stroke
Imaging Guided Patient Selection for Interventional Revascularization Therapy
The primary objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom and with a known core infarct volume at admission.
- Trial name
- START (NCT00963989)
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Penumbra Inc.
Upper Extremity Problem
Vivistim Registry for Paired VNS Therapy (GRASP)
The purpose of the Vivistim Registry for Paired VNS Therapy (GRASP) is to gather real-world information on patients with arm and hand deficits post-stroke who are considering Vivistim System treatment.
- Trial name
- GRASP (NCT05301140)
- Testing
- Vivistim System
- Where
- 16 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- MicroTransponder Inc.
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Acute Ischemic Stroke
Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.
- Trial name
- NCT00756249
- Testing
- Lu AA24493 (CEPO)
- Where
- 5 sites in Finland, France and 3 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take…
- Trial name
- CRYSTAL-AF (NCT00924638)
- Testing
- Reveal® XT Insertable Cardiac Monitor
- Where
- 55 sites in United States, Austria and 12 more
- Volunteers
- 447 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech
Ischemic Stroke, Systemic Embolism
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of…
- Trial name
- LeAAPS (NCT05478304)
- Testing
- AtriClip LAA Exclusion System
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 6,573 people
- Sponsor
- AtriCure, Inc.
Stroke, Acute Ischemic Stroke
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
This study is a multi-center, multi-phase, multi-cohort, prospective, randomized, open, blinded endpoint (PROBE), non-significant risk (NSR) device study including up to 420 evaluable subjects measured with the study device(s)…
- Trial name
- VOICE (NCT05547412)
- Testing
- NovaGuide 2 Intelligent Ultrasound System
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NeuraSignal Inc dba NovaSignal
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ischemic Stroke, Transient Ischemic Attack
AcoArt VI / Vertebral Artery Ostium Stenosis in China
The purpose of this study is to determine whether DEB is not inferior to common bare metal stent using under in long-term vessel patency and inhibiting restenosis in Vertebral Artery Ostium Stenosis
- Trial name
- NCT03910166
- Testing
- drug-coated balloon catheter（Orchid, Acotec）, Intracranial artery stent system（APOLLO）
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Acotec Scientific Co., Ltd
Stroke, Hemiparesis
Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis
The purpose of this study is to assess the safety and effectiveness of cortical stimulation delivered concurrent with rehabilitation activities to enhance motor recovery in patients suffering from hemiparesis affecting the upper…
- Trial name
- EVEREST (NCT00170716)
- Testing
- Cortical Stimulation and rehabilitation, Rehabilitation
- Where
- 21 sites in United States
- Volunteers
- 174 people
- Sponsor
- Northstar Neuroscience
Acute Ischemic Stroke
Compound Edaravone Injection for Acute Ischemic Stroke
1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection versus Edaravone Injection for acute ischemic stroke patients; 2.
- Trial name
- NCT01929096
- Testing
- Compound Edaravone Injection, Edaravone Injection
- Where
- 28 sites in China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cadasil
Efficacy and Safety of Tocotrienols in CADASIL
CADASIL is a paradigmatic cerebral small vessel disease responsible for white-matter lesions, accumulation of lacunes, microbleeds and cerebral atrophy.
- Trial name
- NCT04658823
- Testing
- HOV-12020 (Palm tocotrienols complex)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hovid Berhad